National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
501 total, page 7 of 11
Safety and Dosing Evaluation of REG1 Anticoagulation System
NCT00113997
Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)
NCT00119834
Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
NCT00354328
Biomarkers for Cardiovascular Disease
NCT00109018
Effect of Nitrite on Exercise Physiology and Metabolism
NCT00105222
Establishing a Database of People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Data Project [C-Data])
NCT00529061
Cytokine Gene Polymorphisms in Bone Marrow Failure
NCT00085670
Nitrite Infusion Studies
NCT00102271
Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia
NCT00099996
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
NCT00098280
Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease
NCT00095472
Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
NCT00352482
MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs
NCT00094783
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796
Mutations in Genes Associated With Pentalogy of Cantrell
NCT00083499
Asthma Surveillance and Education in Preschool Settings
NCT00201071
Work, Weight, and Wellness Program: The 3W Program
NCT00123019
STORIES-Stories to Communicate Risk About Tobacco
NCT00101491
Blood Cell Collection for Future Use in Individuals With Fanconi Anemia
NCT00271089
Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease
NCT00090558
Effect of Exercise on Elevated C-reactive Protein Concentrations in Formerly Inactive Adults
NCT00113061
Effects of Exercise Training on Diastolic Heart Function in Postmenopausal Women
NCT00125476
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
NCT00082329
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
NCT00353977
Evaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study)
NCT00739869
Atherosclerosis in the Coronary and Carotid Arteries
NCT00080587
Thymic Tolerance in Pediatric Heart Transplantation
NCT00151164
EW-A-401 to Treat Intermittent Claudication
NCT00080392
Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)
NCT00319488
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
NCT00079313
Technical Development of Strain Rate Echocardiography
NCT00075920
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation
NCT00075335
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
NCT00079391
Cardiac Function in Patients With Hereditary Hemochromatosis
NCT00068159
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
NCT00075829
The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
NCT00074880
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
NCT00065260
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
NCT00072969
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
NCT00542178
Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease
NCT00069654
Treatment of Persistent Wheezing in Infants and Children
NCT00301171
Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network
NCT00113087
Technical Development of Cardiovascular Magnetic Resonance Imaging
NCT00064896
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes
NCT00064727
Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia
NCT00061360
The Framingham Study: Examining DNA Markers and Links to Diseases
NCT00062777
Investigating Cytokine Genes of Stem Cell Donors
NCT00353821
Natural History Study for BEN
NCT00059423
Experimental Bone Marrow Transplant Protocol
NCT00061581
Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia
NCT00050115
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.